261 related articles for article (PubMed ID: 27864344)
1. Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.
Miao L; Liu Q; Lin CM; Luo C; Wang Y; Liu L; Yin W; Hu S; Kim WY; Huang L
Cancer Res; 2017 Feb; 77(3):719-731. PubMed ID: 27864344
[TBL] [Abstract][Full Text] [Related]
2. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.
Hou L; Liu Q; Shen L; Liu Y; Zhang X; Chen F; Huang L
Theranostics; 2018; 8(14):3781-3796. PubMed ID: 30083259
[No Abstract] [Full Text] [Related]
3. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor.
Yunna C; Mengru H; Fengling W; Lei W; Weidong C
Eur J Pharm Biopharm; 2021 Aug; 165():75-83. PubMed ID: 33991610
[TBL] [Abstract][Full Text] [Related]
4. Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.
Hu K; Miao L; Goodwin TJ; Li J; Liu Q; Huang L
ACS Nano; 2017 May; 11(5):4916-4925. PubMed ID: 28414916
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.
Miao L; Wang Y; Lin CM; Xiong Y; Chen N; Zhang L; Kim WY; Huang L
J Control Release; 2015 Nov; 217():27-41. PubMed ID: 26285063
[TBL] [Abstract][Full Text] [Related]
6. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Associated Fibroblast-Targeted Regulation and Deep Tumor Delivery of Chemotherapeutic Drugs with a Multifunctional Size-Switchable Nanoparticle.
Cun X; Chen J; Li M; He X; Tang X; Guo R; Deng M; Li M; Zhang Z; He Q
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39545-39559. PubMed ID: 31617997
[TBL] [Abstract][Full Text] [Related]
8. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment.
Jiang H; Wang S; Zhou X; Wang L; Ye L; Zhou Z; Tang J; Liu X; Teng L; Shen Y
J Control Release; 2018 Sep; 286():254-263. PubMed ID: 30075209
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.
Li W; Little N; Park J; Foster CA; Chen J; Lu J
Mol Pharm; 2021 Aug; 18(8):2889-2905. PubMed ID: 34260250
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment.
McDonald LT; Russell DL; Kelly RR; Xiong Y; Motamarry A; Patel RK; Jones JA; Watson PM; Turner DP; Watson DK; Soloff AC; Findlay VJ; LaRue AC
Neoplasia; 2015 May; 17(5):434-48. PubMed ID: 26025666
[TBL] [Abstract][Full Text] [Related]
11. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Nguyen AH; Elliott IA; Wu N; Matsumura C; Vogelauer M; Attar N; Dann A; Ghukasyan R; Toste PA; Patel SG; Williams JL; Li L; Dawson DW; Radu C; Kurdistani SK; Donahue TR
Oncotarget; 2017 Mar; 8(12):19074-19088. PubMed ID: 27894105
[TBL] [Abstract][Full Text] [Related]
13. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
14. Reflections on depletion of tumor stroma in pancreatic cancer.
Wang WQ; Liu L; Xu JZ; Yu XJ
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):267-272. PubMed ID: 30738097
[TBL] [Abstract][Full Text] [Related]
15. Autophagy is involved in TGF-β1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in tumor microenvironment.
Liu FL; Mo EP; Yang L; Du J; Wang HS; Zhang H; Kurihara H; Xu J; Cai SH
Oncotarget; 2016 Jan; 7(4):4122-41. PubMed ID: 26716641
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy.
Liu M; Song W; Huang L
Cancer Lett; 2019 Apr; 448():31-39. PubMed ID: 30731107
[TBL] [Abstract][Full Text] [Related]
17. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.
Singh RP; Tyagi A; Sharma G; Mohan S; Agarwal R
Clin Cancer Res; 2008 Jan; 14(1):300-8. PubMed ID: 18172282
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
19. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.
Li Y; Hong J; Oh JE; Yoon AR; Yun CO
Int J Cancer; 2018 Jan; 142(2):392-413. PubMed ID: 28929492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
